Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:ATRA NASDAQ:CTMX NASDAQ:ORIC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.69-0.1%$3.85$2.90▼$11.16$325.24M0.183.64 million shs1.23 million shsATRAAtara Biotherapeutics$11.88-2.3%$11.31$5.01▼$18.70$83.75M0.22106,495 shs14,212 shsCTMXCytomX Therapeutics$2.03-3.1%$2.21$0.40▼$3.10$333.94M2.183.22 million shs1.20 million shsORICOric Pharmaceuticals$10.82-0.3%$10.43$3.90▼$14.67$1.05B1.631.09 million shs547,481 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+0.54%+3.65%+1.93%-46.68%-48.54%ATRAAtara Biotherapeutics+3.23%-5.00%+5.37%+37.87%+46.33%CTMXCytomX Therapeutics+0.97%-0.48%+12.37%-24.00%+59.54%ORICOric Pharmaceuticals+3.23%+0.84%+14.08%+12.77%+9.70%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.69-0.1%$3.85$2.90▼$11.16$325.24M0.183.64 million shs1.23 million shsATRAAtara Biotherapeutics$11.88-2.3%$11.31$5.01▼$18.70$83.75M0.22106,495 shs14,212 shsCTMXCytomX Therapeutics$2.03-3.1%$2.21$0.40▼$3.10$333.94M2.183.22 million shs1.20 million shsORICOric Pharmaceuticals$10.82-0.3%$10.43$3.90▼$14.67$1.05B1.631.09 million shs547,481 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune+0.54%+3.65%+1.93%-46.68%-48.54%ATRAAtara Biotherapeutics+3.23%-5.00%+5.37%+37.87%+46.33%CTMXCytomX Therapeutics+0.97%-0.48%+12.37%-24.00%+59.54%ORICOric Pharmaceuticals+3.23%+0.84%+14.08%+12.77%+9.70%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.57Moderate Buy$17.40372.18% UpsideATRAAtara Biotherapeutics 2.80Moderate Buy$21.0076.84% UpsideCTMXCytomX Therapeutics 3.00Buy$5.75183.95% UpsideORICOric Pharmaceuticals 2.89Moderate Buy$17.2959.71% UpsideCurrent Analyst Ratings BreakdownLatest ATRA, ORIC, ALT, and CTMX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/4/2025ORICOric PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.008/14/2025ORICOric PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$20.00 ➝ $17.008/14/2025ORICOric PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$22.00 ➝ $19.008/13/2025ALTAltimmuneHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.008/13/2025ALTAltimmuneUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$26.00 ➝ $24.008/13/2025ALTAltimmuneB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$20.00 ➝ $18.008/13/2025ORICOric PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.008/12/2025ORICOric PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold7/31/2025CTMXCytomX TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.007/10/2025ALTAltimmuneThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell7/10/2025ALTAltimmuneJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetMarket Outperform$25.00 ➝ $15.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$20K16,261.91N/AN/A$1.74 per share2.12ATRAAtara Biotherapeutics$188.67M0.44N/AN/A($16.89) per share-0.70CTMXCytomX Therapeutics$138.10M2.42$0.35 per share5.72($0.01) per share-202.50ORICOric PharmaceuticalsN/AN/AN/AN/A$3.45 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)ATRAAtara Biotherapeutics-$85.40M-$0.43N/AN/AN/A3.07%-8.34%6.61%11/11/2025 (Estimated)CTMXCytomX Therapeutics$31.87M$0.563.62N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)ORICOric Pharmaceuticals-$127.85M-$1.89N/AN/AN/AN/A-51.75%-47.09%11/11/2025 (Estimated)Latest ATRA, ORIC, ALT, and CTMX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million8/12/2025Q2 2025ORICOric Pharmaceuticals-$0.46-$0.47-$0.01-$0.47N/AN/A8/11/2025Q2 2025ATRAAtara Biotherapeutics-$0.32$0.19+$0.51$0.19$4.23 million$17.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AATRAAtara BiotherapeuticsN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/AORICOric PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.0920.4420.44ATRAAtara BiotherapeuticsN/A1.701.70CTMXCytomX TherapeuticsN/A4.204.20ORICOric PharmaceuticalsN/A16.1316.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%ATRAAtara Biotherapeutics70.90%CTMXCytomX Therapeutics67.77%ORICOric Pharmaceuticals95.05%Insider OwnershipCompanyInsider OwnershipALTAltimmune4.40%ATRAAtara Biotherapeutics4.00%CTMXCytomX Therapeutics6.60%ORICOric Pharmaceuticals6.82%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune5088.26 million84.37 millionOptionableATRAAtara Biotherapeutics3307.02 million6.74 millionOptionableCTMXCytomX Therapeutics170164.91 million154.03 millionOptionableORICOric Pharmaceuticals8097.12 million90.50 millionOptionableATRA, ORIC, ALT, and CTMX HeadlinesRecent News About These CompaniesFred Alger Management LLC Sells 40,554 Shares of Oric Pharmaceuticals, Inc. $ORICSeptember 12 at 5:20 AM | marketbeat.comTrexquant Investment LP Invests $425,000 in Oric Pharmaceuticals, Inc. $ORICSeptember 10 at 3:27 AM | marketbeat.com203,006 Shares in Oric Pharmaceuticals, Inc. $ORIC Bought by Parkman Healthcare Partners LLCSeptember 8, 2025 | marketbeat.comORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comOric Pharmaceuticals, Inc. $ORIC Shares Bought by Rafferty Asset Management LLCSeptember 5, 2025 | marketbeat.comOric Pharmaceuticals assumed with a Buy at GuggenheimSeptember 4, 2025 | msn.comAlkeon Capital Management LLC Buys 100,000 Shares of Oric Pharmaceuticals, Inc. $ORICSeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Takes $7.81 Million Position in Oric Pharmaceuticals, Inc. $ORICSeptember 4, 2025 | marketbeat.comFrazier Life Sciences Management L.P. Has $7.87 Million Stock Position in Oric Pharmaceuticals, Inc. $ORICSeptember 4, 2025 | marketbeat.comORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents at Citi's Biopharma Back to School Conference - SlideshowSeptember 3, 2025 | seekingalpha.comORIC Pharmaceuticals, Inc. (ORIC) Pharmaceuticals, Inc. Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 3, 2025 | seekingalpha.comStocks To Watch: Oric Pharmaceuticals Sees RS Rating Jump To 82September 3, 2025 | msn.comNuveen LLC Makes New Investment in Oric Pharmaceuticals, Inc. $ORICSeptember 3, 2025 | marketbeat.comDAFNA Capital Management LLC Purchases New Holdings in Oric Pharmaceuticals, Inc. $ORICSeptember 1, 2025 | marketbeat.comORIC® Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Given Average Rating of "Moderate Buy" by BrokeragesAugust 27, 2025 | marketbeat.comThis ORIC Pharmaceuticals Insider Increased Their Holding In The Last YearAugust 24, 2025 | finance.yahoo.comOric Pharmaceuticals, Inc. (NASDAQ:ORIC) Short Interest Down 45.0% in JulyAugust 20, 2025 | marketbeat.comORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief ...August 19, 2025 | bakersfield.comBORIC Pharmaceuticals: ORIC Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical OfficerAugust 19, 2025 | finanznachrichten.deORIC Pharmaceuticals Reports Q2 2025 Financial ResultsAugust 19, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 20252 Data Center REITs That Look Good in Any PortfolioBy Sam Quirke | September 8, 2025Medtronic: The Opportunity Gets Healthier for Income InvestorsBy Thomas Hughes | August 19, 2025Joby Aviation: Why a Historic Flight Outweighs Analyst DowngradesBy Jeffrey Neal Johnson | August 19, 2025Buy, Sell, or Hold? Insiders Pile Into These 3 Healthcare StocksBy Thomas Hughes | August 19, 2025ATRA, ORIC, ALT, and CTMX Company DescriptionsAltimmune NASDAQ:ALT$3.68 -0.01 (-0.14%) As of 03:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Atara Biotherapeutics NASDAQ:ATRA$11.88 -0.29 (-2.34%) As of 03:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma. Its CAR T immunotherapy pipeline products include ATA3219, currently in Phase 1 trials, as well as ATA3431, under preclinical trials for the treatment of B-cell malignancies and autoimmune diseases; and ATA188 that is in Phase 2 clinical trials to treat multiple sclerosis. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.CytomX Therapeutics NASDAQ:CTMX$2.02 -0.07 (-3.11%) As of 03:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.Oric Pharmaceuticals NASDAQ:ORIC$10.82 -0.04 (-0.34%) As of 03:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
